Meanwhile, the BSE Sensex was down 28.53 points, or 0.16%, to 17,297.48.
On BSE, 4.05 lakh shares were traded in the counter as against an average daily volume of 78,031 shares in the past one quarter.
The stock hit a high of Rs 26.05 and a low of Rs 24.50 so far during the day. The stock had hit a 52-week high of Rs 28.22 on 28 May 2009 and a 52-week low of Rs 9.10 on 13 March 2009.
The small-cap stock had underperformed the market over the past one month till 17 October 2009, rising 1.64% as compared to the Sensex's 3.68% rise. It had outperformed the market in the past one quarter, gaining 40.79% as compared to the Sensex's return of 17.50%.
The company's equity capital is Rs 15.23 crore. Face value per share is Rs 1.
The current price of Rs 26.05 discounts the company's Q1 June 2009 annualized EPS of Rs 5.37, by a PE multiple of 4.85.
Nectar Lifesciences' net sales rose 7.56% to Rs 253.76 crore in Q2 September 2009 over Q2 September 2008. The company announced the results during trading hours today, 20 October 2008.
The company is engaged in manufacturing bulk drugs. The products include cefotaxime acid, cefuroxime acid, mica acid, sodium bi carbonate, tetra hydro furon, atorvastatin, cefalothin, cefdinir, cefprozil and clythromycin. The plants are located at Punjab, Himachal Pradesh and Jammu & Kashmir.